However, in neuroblastoma patients, Costa et al. demonstrated that high STK25 levels in tumors are associated with a better prognosis and that STK25 acts as an effector of the death signaling pathway that is initiated by TrkA and CCM2 [41]. This evidence concerns the gene NTRK1 and neuroblastoma.